Literature DB >> 22416052

Receptor conformations involved in dopamine D(2L) receptor functional selectivity induced by selected transmembrane-5 serine mutations.

J Corey Fowler1, Supriyo Bhattacharya, Jonathan D Urban, Nagarajan Vaidehi, Richard B Mailman.   

Abstract

Although functional selectivity is now widely accepted, the molecular basis is poorly understood. We have studied how aspects of transmembrane region 5 (TM5) of the dopamine D(2L) receptor interacts with three rationally selected rigid ligands (dihydrexidine, dinapsoline, and dinoxyline) and the reference compounds dopamine and quinpirole. As was expected from homology modeling, mutation of three TM5 serine residues to alanine (S5.42A, S5.43A, S5.46A) had little effect on antagonist affinity. All three mutations decreased the affinity of the agonist ligands to different degrees, S5.46A being somewhat less affected. Four functions [adenylate cyclase (AC), extracellular signal-regulated kinase 1/2 phosphorylation (MAPK), arachidonic acid release (AA), and guanosine 5'-O-(3-thio)triphosphate binding (GTPγS)] were assessed. The intrinsic activity (IA) of quinpirole was unaffected by any of the mutations, whereas S5.42A and S5.46A mutations abolished the activity of dopamine and the three rigid ligands, although dihydrexidine retained IA at MAPK function only with S5.42A. Remarkably, S5.43A did not markedly affect IA for AC and MAPK for any of the ligands and eliminated AA activity for dinapsoline and dihydrexidine but not dinoxyline. These data suggest that this mutation did not disrupt the overall conformation or signaling ability of the mutant receptors but differentially affected ligand activation. Computational studies indicate that these D(2) agonists stabilize multiple receptor conformations. This has led to models showing the stabilized conformations and interhelical and receptor-ligand contacts corresponding to the different activation pathways stabilized by various agonists. These data provide a basis for understanding D(2L) functional selectivity and rationally discovering functionally selective D(2) drugs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22416052      PMCID: PMC3362898          DOI: 10.1124/mol.111.075457

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  45 in total

1.  Modeller: generation and refinement of homology-based protein structure models.

Authors:  András Fiser; Andrej Sali
Journal:  Methods Enzymol       Date:  2003       Impact factor: 1.600

2.  Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist.

Authors:  T W Lovenberg; W K Brewster; D M Mottola; R C Lee; R M Riggs; D E Nichols; M H Lewis; R B Mailman
Journal:  Eur J Pharmacol       Date:  1989-07-04       Impact factor: 4.432

3.  Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist.

Authors:  K J Darney; M H Lewis; W K Brewster; D E Nichols; R B Mailman
Journal:  Neuropsychopharmacology       Date:  1991-11       Impact factor: 7.853

4.  Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2'0 acetylation by acetic anhydride in aqueous solution.

Authors:  J F Harper; G Brooker
Journal:  J Cyclic Nucleotide Res       Date:  1975

5.  Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs.

Authors:  Jason D Kilts; Hilary S Connery; Elaine G Arrington; Mechelle M Lewis; Cindy P Lawler; Gerry S Oxford; Karen L O'Malley; Richard D Todd; Bonita L Blake; David E Nichols; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

6.  Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor.

Authors:  C D Strader; M R Candelore; W S Hill; I S Sigal; R A Dixon
Journal:  J Biol Chem       Date:  1989-08-15       Impact factor: 5.157

7.  Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

Authors:  David A Shapiro; Sean Renock; Elaine Arrington; Louis A Chiodo; Li-Xin Liu; David R Sibley; Bryan L Roth; Richard Mailman
Journal:  Neuropsychopharmacology       Date:  2003-05-21       Impact factor: 7.853

8.  Contributions of conserved serine residues to the interactions of ligands with dopamine D2 receptors.

Authors:  B A Cox; R A Henningsen; A Spanoyannis; R L Neve; K A Neve
Journal:  J Neurochem       Date:  1992-08       Impact factor: 5.372

9.  trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist.

Authors:  W K Brewster; D E Nichols; R M Riggs; D M Mottola; T W Lovenberg; M H Lewis; R B Mailman
Journal:  J Med Chem       Date:  1990-06       Impact factor: 7.446

10.  Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands.

Authors:  P S Charifson; J P Bowen; S D Wyrick; A J Hoffman; M Cory; A T McPhail; R B Mailman
Journal:  J Med Chem       Date:  1989-09       Impact factor: 7.446

View more
  14 in total

Review 1.  Advances in receptor conformation research: the quest for functionally selective conformations focusing on the β2-adrenoceptor.

Authors:  Anthony Yiu-Ho Woo; Ying Song; Weizhong Zhu; Rui-Ping Xiao
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

2.  Molecular Determinants of the Intrinsic Efficacy of the Antipsychotic Aripiprazole.

Authors:  Carmen Klein Herenbrink; Ravi Verma; Herman D Lim; Anitha Kopinathan; Alastair Keen; Jeremy Shonberg; Christopher J Draper-Joyce; Peter J Scammells; Arthur Christopoulos; Jonathan A Javitch; Ben Capuano; Lei Shi; J Robert Lane
Journal:  ACS Chem Biol       Date:  2019-08-05       Impact factor: 5.100

3.  Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model.

Authors:  Clinton E Canal; Raymond G Booth; Drake Morgan
Journal:  Neuropharmacology       Date:  2013-01-23       Impact factor: 5.250

4.  Tyrosine 308 is necessary for ligand-directed Gs protein-biased signaling of β2-adrenoceptor.

Authors:  Anthony Yiu-Ho Woo; Krzysztof Jozwiak; Lawrence Toll; Mary J Tanga; Joseph A Kozocas; Lucita Jimenez; Ying Huang; Ying Song; Anita Plazinska; Karolina Pajak; Rajib K Paul; Michel Bernier; Irving W Wainer; Rui-Ping Xiao
Journal:  J Biol Chem       Date:  2014-05-15       Impact factor: 5.157

5.  Ligand-directed bias of G protein signaling at the dopamine D2 receptor.

Authors:  Ee Von Moo; Kasper Harpsøe; Alexander S Hauser; Ikuo Masuho; Hans Bräuner-Osborne; David E Gloriam; Kirill A Martemyanov
Journal:  Cell Chem Biol       Date:  2021-07-23       Impact factor: 8.116

6.  Active-state models of ternary GPCR complexes: determinants of selective receptor-G-protein coupling.

Authors:  Ralf C Kling; Harald Lanig; Timothy Clark; Peter Gmeiner
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

7.  Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs.

Authors:  John D McCorvy; Kyle V Butler; Brendan Kelly; Katie Rechsteiner; Joel Karpiak; Robin M Betz; Bethany L Kormos; Brian K Shoichet; Ron O Dror; Jian Jin; Bryan L Roth
Journal:  Nat Chem Biol       Date:  2017-12-11       Impact factor: 15.040

8.  Preferential Coupling of Dopamine D2S and D2L Receptor Isoforms with Gi1 and Gi2 Proteins-In Silico Study.

Authors:  Justyna Żuk; Damian Bartuzi; Dariusz Matosiuk; Agnieszka A Kaczor
Journal:  Int J Mol Sci       Date:  2020-01-09       Impact factor: 5.923

Review 9.  Structural Insights into Ligand-Receptor Interactions Involved in Biased Agonism of G-Protein Coupled Receptors.

Authors:  Krzysztof Jóźwiak; Anita Płazińska
Journal:  Molecules       Date:  2021-02-06       Impact factor: 4.411

10.  Active-state model of a dopamine D2 receptor-Gαi complex stabilized by aripiprazole-type partial agonists.

Authors:  Ralf C Kling; Nuska Tschammer; Harald Lanig; Timothy Clark; Peter Gmeiner
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.